Nipocalimab demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study
First FcRn blocker to demonstrate sustained disease control over 24 weeks in antibody positive adolescents aged 12
–
17 years, broadening the population in which nipocalimab has been studied
SAVANNAH, Ga. (October 15, 2024)
– Johnson & Johnson...
Zur Pressemeldung auf www.jnj.com